Partners
Commercial Partners
ImClone Systems (a subsidiary of Eli Lilly) developer of anti-VEGFR-3 antibody (IMC-3C5) drug for treatment of cancer.
Ark Therapeutics (LSE:AKT) developer of VEGF-D gene therapy.
Healthscope Limited, development partner for Cancers of Unknown Primary (CUP) molecular diagnostic.
R&D Systems Inc., non-exclusive provider of VEGF-C, VEGF-D and VEGFR-3 research reagents.
Merck Millipore, non-exclusive provider of VEGF-C, VEGF-D and VEGFR-3 research reagents
Perkin Elmer, non-exclusive provider of VEGF-C, VEGF-D and VEGFR-3 research reagents
ReliaTech GmbH, non-exclusive provider of VEGF-C, VEGF-D and VEGFR-3 research reagents
Bio-Rad, non-exclusive provider of VEGF-C, VEGF-D
Ceres Pty Ltd, a 100% subsidiary of Circadian Technologies Limited
Opthea Pty Ltd, a 100% subsidiary of Circadian Technologies Limited
Scientific Collaborators
Circadian collaborates with some of the worlds most renowned researchers in the fields of angiogenesis, lymphangiogenesis, cancer and ophthalmology.
Laboratory of Prof. Kari Alitalo, University of Helsinki discoverer of VEGFR-3 and its ligand VEGF-C.
Laboratory of Profs. Steve Stacker and Marc Achen, Peter MacCallum Cancer Institute, discoverers of the VEGFR-3 ligand VEGF-D.
Laboratory of Prof. Reza Dana, Schepens Eye Research Institute at Harvard University.
Peter MacCallum Cancer Institute, laboratory of Prof. David Bowtell and NICTA (National ICT Australia) molecular discovery laboratory led by Prof. Adam Kowalczyk, in the development of CUP diagnostics.
University of Cincinnati, through the laboratory of Prof. Frank McCormack in the development of VEGF-D diagnositcs for the diagnosis of lymphangioleiomyomatosis (LAM)
New partnership opportunities
For partnership interest in any Circadian program, please email info@circadian.com.au or call +61 3 9826 0399.